Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) Revenue (2016 - 2025)

Immucell (ICCC) has disclosed Revenue for 16 consecutive years, with $5.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Revenue rose 0.61% year-over-year to $5.5 million, compared with a TTM value of $27.8 million through Sep 2025, up 48.17%, and an annual FY2024 reading of $26.5 million, up 51.64% over the prior year.
  • Revenue was $5.5 million for Q3 2025 at Immucell, down from $6.4 million in the prior quarter.
  • Across five years, Revenue topped out at $8.1 million in Q1 2025 and bottomed at $3.4 million in Q1 2023.
  • Average Revenue over 5 years is $5.4 million, with a median of $5.4 million recorded in 2021.
  • The sharpest move saw Revenue plummeted 42.55% in 2023, then surged 110.58% in 2024.
  • Year by year, Revenue stood at $5.4 million in 2021, then decreased by 28.16% to $3.9 million in 2022, then surged by 37.99% to $5.4 million in 2023, then skyrocketed by 43.63% to $7.8 million in 2024, then dropped by 28.96% to $5.5 million in 2025.
  • Business Quant data shows Revenue for ICCC at $5.5 million in Q3 2025, $6.4 million in Q2 2025, and $8.1 million in Q1 2025.